Corbus Pharmaceuticals reported promising results Thursday from an early stage clinical study of a potential anti-inflammatory drug for people with cystic fibrosis.
Site Search
Showing 1 - 10 of 108 results
News
|
|
2 min read
News
|
|
3 min read
The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
News
|
|
2 min read
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
News
|
|
3 min read
In addition to the typical travel headaches, people with cystic fibrosis must also consider other things related to their health. This section will discuss ways to be as prepared as possible for your trip so that you can spend less time on travel hassles and more time enjoying yourself.
Everyone needs a break from time to time. In fact, sometimes a family trip or a getaway with friends is just what the doctor ordered. In this section, we'll discuss ways to manage your CF while traveling so that you return home as healthy as when you left.
Overseas travel can be a challenge, even for the most experienced of travelers. If you have cystic fibrosis and are considering traveling abroad, early planning can help.
The Cystic Fibrosis Foundation's successful business model was at the center of a congressional briefing in Washington, D.C., today, which focused on strategies for jump-starting drug development for rare diseases.
News
|
|
2 min read
News
|
|
2 min read
News
|
|
1 min read